JP2003521914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003521914A5 JP2003521914A5 JP2001557910A JP2001557910A JP2003521914A5 JP 2003521914 A5 JP2003521914 A5 JP 2003521914A5 JP 2001557910 A JP2001557910 A JP 2001557910A JP 2001557910 A JP2001557910 A JP 2001557910A JP 2003521914 A5 JP2003521914 A5 JP 2003521914A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- human
- mammal
- exchange column
- human mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 20
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 20
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 15
- 102000044507 human SERPING1 Human genes 0.000 description 15
- 238000000034 method Methods 0.000 description 11
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 201000007120 C1 inhibitor deficiency Diseases 0.000 description 4
- 206010019860 Hereditary angioedema Diseases 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17931000P | 2000-01-31 | 2000-01-31 | |
| EP00200320.0 | 2000-01-31 | ||
| US60/179,310 | 2000-01-31 | ||
| EP00200320 | 2000-01-31 | ||
| US18758000P | 2000-03-07 | 2000-03-07 | |
| EP00200810 | 2000-03-07 | ||
| US60/187,580 | 2000-03-07 | ||
| EP00200810.0 | 2000-03-07 | ||
| PCT/NL2001/000068 WO2001057079A2 (en) | 2000-01-31 | 2001-01-31 | C1 inhibitor produced in the milk of transgenic mammals |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011270236A Division JP2012050465A (ja) | 2000-01-31 | 2011-12-09 | トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003521914A JP2003521914A (ja) | 2003-07-22 |
| JP2003521914A5 true JP2003521914A5 (enExample) | 2008-02-28 |
Family
ID=56290105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001557910A Withdrawn JP2003521914A (ja) | 2000-01-31 | 2001-01-31 | トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1252184B1 (enExample) |
| JP (1) | JP2003521914A (enExample) |
| AT (1) | ATE382635T1 (enExample) |
| CA (1) | CA2398707C (enExample) |
| DE (2) | DE122011000002I1 (enExample) |
| DK (1) | DK1252184T3 (enExample) |
| ES (1) | ES2299473T3 (enExample) |
| PT (1) | PT1252184E (enExample) |
| WO (1) | WO2001057079A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10690670B2 (en) | 2013-01-20 | 2020-06-23 | Dyax Corp. | Assays for determining levels of plasma protease C1 inhibitor |
| US11754570B2 (en) | 2019-04-16 | 2023-09-12 | Takeda Pharmaceutical Company Limited | Methods for quantitation of functional C1 esterase inhibitor (FC1-INH) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067713B2 (en) * | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| DE10112617A1 (de) * | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
| PL376318A1 (en) * | 2002-10-17 | 2005-12-27 | Pharming Intellectual Property B.V. | Protein modification |
| EP1947116B1 (en) | 2003-02-10 | 2017-06-21 | 2-BBB Medicines B.V. | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
| HUE052154T2 (hu) * | 2003-05-16 | 2021-04-28 | Pharming Intellectual Property B V | Rövid felezési idejû C1 inhibitor tranziens kezeléshez |
| HRP20110622T1 (hr) * | 2005-12-21 | 2011-09-30 | Pharming Intellectual Property B.V. | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
| FR2901796A1 (fr) * | 2006-05-31 | 2007-12-07 | Lab Francais Du Fractionnement | Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait |
| FR2901707B1 (fr) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| EP3028716B1 (en) | 2006-10-10 | 2020-09-16 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
| JP5507555B2 (ja) * | 2008-06-30 | 2014-05-28 | チョ−エー・ファーム・カンパニー・リミテッド | 豚のαＳ１カゼイン遺伝子、そのプロモーター、及びその用途 |
| WO2010087702A1 (en) | 2009-01-30 | 2010-08-05 | Stichting Katholieke Universiteit | TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject |
| WO2011034421A1 (en) | 2009-09-16 | 2011-03-24 | Stichting Het Nederlands Kanker Instituut | Fra-1 target genes as drug targets for treating cancer |
| EP2305717A1 (en) | 2009-09-21 | 2011-04-06 | Koninklijke Nederlandse Akademie van Wetenschappen | Inhibiting TNIK for treating colon cancer |
| EP2354244A1 (en) | 2010-02-04 | 2011-08-10 | Stichting Top Institute Food and Nutrition | MBL2 as a marker of liver-specific insulin resistance |
| EP2354245A1 (en) | 2010-02-04 | 2011-08-10 | Stichting Top Institute Food and Nutrition | MBL2 as a marker of hepatic PPAR- activity |
| WO2012026820A2 (en) | 2010-08-27 | 2012-03-01 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating prostate cancer |
| EP2465928A1 (en) | 2010-12-16 | 2012-06-20 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Treatment of Th17-mediated diseases |
| EP2866826B1 (en) | 2012-06-27 | 2025-08-06 | Meiragtx UK II Limited | Combination for treating an inflammatory disorder |
| EP2912065A4 (en) | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF |
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| SI2968434T1 (sl) | 2013-03-15 | 2017-11-30 | Shire Viropharma Incorporated, | C1-INH sestavki za uporabo pri preprečevanju in zdravljenju hereditarnega angioedema (HAE) |
| US10758550B2 (en) | 2013-10-04 | 2020-09-01 | Glenmark Specialty S.A. | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
| WO2016080830A2 (en) | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating pancreatic cancer |
| BR112017021289A2 (en) | 2015-04-06 | 2018-06-26 | Bioverativ Usa Inc. | humanized anti-c1s antibodies and methods of use |
| WO2017087882A1 (en) * | 2015-11-19 | 2017-05-26 | Shire Human Genetic Therapies, Inc. | Recombinant human c1 esterase inhibitor and uses thereof |
| EP3525583B8 (en) | 2016-10-12 | 2025-09-10 | Bioverativ USA Inc. | Anti-c1s antibodies and methods of use thereof |
| WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| WO2019166556A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Treatment and prevention of pre-eclampsia |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| CA3225079A1 (en) | 2021-07-09 | 2023-01-12 | Bruno Giannetti | Using c1 esterase inhibitor to treat viral infection-related symptoms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601034B1 (fr) * | 1986-07-03 | 1989-11-17 | Pasteur Institut | Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese |
| JPH05503001A (ja) * | 1989-10-27 | 1993-05-27 | スティッチング セントラール ラボラトリウム ファン デ ブルートトランスフュジエディエンスト ファン ヘット ネデールランツェ ローデ クルイス | Ｃ１インヒビターミューティンおよびその利用 |
| WO1992022320A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
| DE4227762A1 (de) * | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
| US6713662B1 (en) * | 1994-07-27 | 2004-03-30 | Pharming Intellectual Property B.V. | Production of collagen in the milk of transgenic mammals |
| GB9807464D0 (en) * | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
-
2001
- 2001-01-31 ES ES01906428T patent/ES2299473T3/es not_active Expired - Lifetime
- 2001-01-31 CA CA2398707A patent/CA2398707C/en not_active Expired - Lifetime
- 2001-01-31 DK DK01906428T patent/DK1252184T3/da active
- 2001-01-31 EP EP01906428A patent/EP1252184B1/en not_active Expired - Lifetime
- 2001-01-31 WO PCT/NL2001/000068 patent/WO2001057079A2/en not_active Ceased
- 2001-01-31 PT PT01906428T patent/PT1252184E/pt unknown
- 2001-01-31 JP JP2001557910A patent/JP2003521914A/ja not_active Withdrawn
- 2001-01-31 AT AT01906428T patent/ATE382635T1/de active
- 2001-01-31 DE DE122011000002C patent/DE122011000002I1/de active Pending
- 2001-01-31 DE DE60132169T patent/DE60132169T2/de not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10690670B2 (en) | 2013-01-20 | 2020-06-23 | Dyax Corp. | Assays for determining levels of plasma protease C1 inhibitor |
| US11892450B2 (en) | 2013-01-20 | 2024-02-06 | Takeda Pharmaceutical Company Limited | Evaluation, assays and treatment of pKal-mediated disorders |
| US11754570B2 (en) | 2019-04-16 | 2023-09-12 | Takeda Pharmaceutical Company Limited | Methods for quantitation of functional C1 esterase inhibitor (FC1-INH) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003521914A5 (enExample) | ||
| CA2398707A1 (en) | C1 inhibitor produced in the milk of transgenic mammals | |
| JP2012050465A5 (enExample) | ||
| Lusher et al. | Severe factor VIII and factor IX deficiency in females | |
| Kimelberg et al. | The effect of entrapment in liposomes on the in vivo distribution of [3H] methotrexate in a primate | |
| Ruddy et al. | C3b inactivator of man: II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b | |
| Katz | Iron and protein kinetics studied by means of doubly labeled human crystalline transferrin | |
| CA1329760C (en) | Plasma and recombinant protein formulations in high ionic strength media | |
| JPH11509721A (ja) | 高純度フォンビルブラント因子の入手方法 | |
| JPH0742235B2 (ja) | 自己免疫性疾病の予防・治療剤 | |
| WO1998023289A1 (en) | MODULATION OF IgG BINDING TO FcRn | |
| JPS6230A (ja) | 悪性腫瘍性貧血治療剤 | |
| ES2315255T3 (es) | Utilizacion de trombopoyetina como medicamento para la terapia y la prevencion de trombocitopenia. | |
| BR112013029769B1 (pt) | Levedura recombinante compreendendo sequência de ácido nucleico que codifica h- ferritina, composição que a compreende e uso das mesmas | |
| Barandun et al. | Clinical tolerance and catabolism of plasmin-treatedγ-globulin for intravenous application | |
| Linder et al. | Copper transport in mammals | |
| Choo et al. | Expression of active human blood clotting factor IX in transgenic mice: use of a cDNA with complete mRNA sequence | |
| Kesteven et al. | Inhibitor to factor VIII in mild haemophilia | |
| Smith et al. | Evidence of stem-cell competition in children with malignant disease: a controlled study of hypertransfusion | |
| Bertolini | The purification of plasma proteins for therapeutic use | |
| JP3634359B2 (ja) | Ｔｃｆ−▲ｉｉ▼を有効成分とする血液凝固正常化剤 | |
| Baltz et al. | In vivo turnover studies of C-reactive protein | |
| Hasegawa et al. | Transferrin Receptor on Chick Fibroblast Cell Surface and the Binding Affinity in Relevance to the Growth Promoting Activity of Transferrin: (transferrin/receptor/cultured fibroblast/molecular recognition/class dependent specificity) | |
| Hoffbrand et al. | Effect of chronic nutritional iron deficiency on the small intestinal disaccharidase activities of growing dogs | |
| AU725441B2 (en) | An agent for preventing and/or treating multiple organ failure |